Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
What the term means
MIT is mitragynine, the principal alkaloid of the kratom leaf. 13 is 13-OH, the corydalis-derived alkaloid we supply. A MIT + 13 product contains both — mitragynine at whatever level the formula calls for, and 13-OH typically at 25 to 40 milligrams per serving.
You will see it written MIT+13, MIT + 13-OH, or "mitragynine with 13." They all mean the same thing.
Why brands build it
Walk a shelf. Almost every product on it is mitragynine, in a tablet or a shot, with a different label. Differentiation has traditionally come from adding a second alkaloid — and every second alkaloid the category has reached for has now been named in a federal scheduling action.
13-OH is not one of those, because it is not built on mitragynine chemistry at all. Adding it changes the product in ways a customer can actually notice, without introducing a compound with a scheduling problem attached. The fuller version of that argument is here.
What it changes in the product
What formulators report, consistently:
- Reduced sensory harshness compared with the same product without it — the most cited reason for adopting it.
- A fuller, rounder overall character.
- The ability to hit the target at a lower mitragynine inclusion, because 13-OH carries part of the profile.
That third point is the strategically interesting one. Less mitragynine per serving means a shorter ingredient statement and a lighter total alkaloid load — a product that is easier to defend and easier to stand behind. Effects and the evidence behind them.
What it does not change
Important, and often misunderstood
Adding 13-OH to a mitragynine product does not remove that product from the scope of state kratom acts. The mitragynine is still there, and those statutes apply to it exactly as before. What 13-OH adds is differentiation, not an exemption.
If your goal is to be outside kratom regulation entirely, that requires a product with no Mitragyna speciosa material at all — kava, kanna, and 13-OH, for instance. That is the kratom-free path, covered here.
So: MIT + 13 keeps your existing compliance posture and improves your product. Kratom-free changes your compliance posture and opens different channels. Plenty of brands run both.
How to implement it
- Start at 30 mg per serving. That is the most common inclusion and a sensible first trial. Dosing detail.
- Run three bench samples — control, additive, and a version with mitragynine reduced. The third one usually decides it.
- Decide your label story. You are declaring an additional ingredient; work out how you describe it before artwork goes to print. What you can and cannot say.
- Lock the spec and book production. Co-packing lead time is fifteen days from packaging in hand. How a run works.
Common questions
No. If mitragynine is present, the product contains kratom-derived material and state kratom acts apply exactly as before. A kratom-free product contains no Mitragyna speciosa material at all. The kratom-free path.
25–40 mg per serving, most commonly 30 mg. Full dosing guidance.
No — plenty of brands add 13-OH and leave mitragynine unchanged. But the option to reduce it is where much of the value sits, so it is worth benching that version before you decide.
Yes. Tablets and liquid shots, under your brand, manufactured under cGMP. Minimums are 25,000 tablets or 15,000 shots. Co-packing detail.
The 13-OH component is not a scheduled substance and adds no new restriction. The mitragynine component carries whatever obligations already apply to it in your markets. Neither of those statements is legal advice — review your specific product and markets with your own counsel. Regulatory summary.